Latest Breaking News On - Jiangsu yahong meditech - Page 1 : comparemela.com

Olaparib plus abiraterone acetate delayed disease progression and improved outcomes in patients with BRCA-, ATM- and CDK12-mutated mCRPC.

United statesBristol myers squibbBristol myers squibb sanofiMedivation astellasImmunitybio incyteMerck seronoNonagen bioscienceAstellas pharmaJiangsu yahong meditechTelix pharmaceuticalsCarolina urologic research centerAsieris pharmaceuticalsFoundation medicineClarity pharmaceuticalsAragon pharmaceuticalsSpeciality networks